Last updated on March 2018

L. Casei DG in Patients With Irritable Bowel Syndrome.


Brief description of study

To assess the effect of L. casei DG (Lactobacillus paracasei CNCMI1572; Enterolactis plus) on abdominal symptoms and gut microbiota metabolism/composition in non constipated patients with IBS (Irritable Bowel Syndrome). Patients will be randomized to receive L. casei DG capsules, b.i.d. for 12 weeks the a 4 weeks Follow Up period will follow.

Clinical Study Identifier: NCT03449628

Contact Investigators or Research Sites near you

Start Over

Fabio PAce

A.O. Bolognini
Seriate, Italy
  Connect »

Luca Pastorelli

Policlinico San Donato
San Donato Milanese, Italy
  Connect »

Piero Portincasa

Gastroenterologia Universitaria Policlinico Giovanni XXIII
Bari, Italy
  Connect »

Bastianello Germanà, Dr

Azienda ULSS 1
Belluno, Italy
  Connect »

Giovanni Barbara, Professor

Azienda Ospedaliero-Universitaria S. Orsola Malpighi
Bologna, Italy
  Connect »

Matteo Neri, professor

Ospedale SS. Annunziata
Chieti, Italy
  Connect »

Guido Basilisco, doctor

Fondazione IRCCS Policlinico
Milano, Italy
  Connect »

Rosario Cuomo, Professor

Policlinico
Napoli, Italy
  Connect »

Gerardo Nardone

Policlinico Federico II
Napoli, Italy
  Connect »

Francesca Galeazzi

Azienda Ospedaliera di Padova
Padova, Italy
  Connect »

Antonio Di Sabatino

Fondazione IRCCS Policlinico S. Matteo
Pavia, Italy
  Connect »

Santino Marchi, Professor

U.O. Gastroenterologia Universitaria
Pisa, Italy
  Connect »

Michele Cicala, Professor

Policlinico Universitario Campus Biomedico
Roma, Italy
  Connect »

Rocco Cosentino

A.O. San Camillo-Forlanini
Roma, Italy
  Connect »

Bruno Annibale

hospitall Sant'Andrea
Roma, Italy
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.